Almost AGI? The latest AI models still haven’t shown they can beat humans at carb counting…
This is a follow-up to I asked AI to count my carbs 27,000 times. It couldn’t give me the same answer twice. The full preprint […]
Articles by admin
Zucara’s ZT-01: what could taking the brake off glucagon do?
ZT-01 aims to restore glucagon counterregulation during hypoglycaemia. But type 1 diabetes already produces glucagon at the wrong time — and Zucara’s own human data show SSTR2 blockade raises glucagon, glucose and insulin requirements during euglycaemia. What will the trials tell us about its longer term effects?
More Bolus, Less Basal: What Happens When oref Loops Run More Frequently
When you give an oref based hybrid closed loop minute by minute data, what happens to it’s insulin delivery choices? This is where we find out.
Your CGM Knows You Ate. It Can’t Tell What You Ate.
How much of a meal signal is there in glucose data, and what can you do with it? This article describes a deep dive into a large dataset and tells us what it finds.
Beyond Carb Counting: Boost’s Evolution — and the Limits of “Fully Closed Loop”
An update on Boost, how it helps remove carb counting, and the techniques and mechanisms we’ve used to try and get there.
Bolt AI into your loop and you might just have become a medical device manufacturer
Embedded AI is starting to appear in open source AID systems, offered as copy and paste, bring your own key, or a service the project runs. A year of measuring these models says the clinical risk is much the same in all three. The regulatory position is not, and the intuition about which is safest runs backwards.
The world’s first digital endo that asks AI to fix your AID settings, and why you should keep your money.
Ask once and you get an answer. Ask fifty times and you get eighteen different pairs of safety limits, a headline that flips one time in five, and an app that accepts them all. Inside the £4.49 app that turns your diabetes data into chatbot advice on your OS-AID settings.
A world of pure imagination: AI, diabetes and the data we can’t get at
Search the app stores for diabetes and AI and you will find a remarkable number of applications doing exactly one thing. You point a camera […]
Why is the cheese sandwich the downfall of AI carb counting, even with “3D scanning”?
A slightly rhetorical question, I’ll admit, but a pertinent one. Once again, I have been trying out the latest (read most heavily pushed on Facebook […]
The Libre Duo. A platform prototype to move care from the hospital to the home?
Abbott has put glucose and ketones on the same wearable, and the launch coverage is all about DKA. Worth having if you’re on a pump, which is fine as far as it goes, but it misses the bit that makes this interesting. Because if you look at what Abbott has actually built across its other divisions, and what they’ve patented alongside it, the Libre Duo doesn’t really look like a ketone sensor. It looks like the platform prototype and the first visible piece of an infrastructure designed to move chronic disease care out of outpatients and into the home. And the policy environment for that shift has just been locked in on both sides of the Atlantic for the next five years.